Search Results
The Gift of Time: Giving More Moments to Blood Cancer Patients
As we transition from one year to the next, we often reflect on milestones achieved, challenges faced, and moments shared with those we love. It’s a time to focus on what’s most important—family, community, and how we’ll spend our time going forward. At the Leukemia & Lymphoma Society (LLS), we know that time is more than just a passing moment for blood cancer patients. It’s the most valuable gift they can receive.
Meet the Researcher: Maria Figueroa, MD
Our “Meet the Researcher” series on The LLS Blog shares what our outstanding LLS-funded researchers are working on, the incredible impact they’re making in the fight against blood cancer, and what inspires their efforts to find better treatments and cures. Dr. Maria “Ken” Figueroa, Associate Professor and Co-Leader of the Cancer Epigenetics Research Program at Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, is focused on an exciting area of research called epigenetics.
Exercise for blood cancer patients
Table of contents:
Towards Equity in Specialized Cancer Care for Adolescents and Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Our study is designed to directly inform the pathways through which health insurance influences access to care at an SCC for individuals with AYA ALL using a combination of cancer registry, survey, and cost-benefit analyses.Gilteritinib
Gilteritinib is a indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Brexucabtagene autoleucel
Brexucabtagene autoleucel is FDA approved for the treatment of
- Adult patients with relapsed or refractory mantle cell lymphoma (MCL).
This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Filgrastim
Filgrastim is FDA approved to
Nutrition Advice from a Dietitian & Blood Cancer Survivor
76-year-old Barbara Borrell is a woman who wears many hats – a 50+ year registered dietitian, nutrition consultant and educator, cancer advocate, volunteer with The Leukemia & Lymphoma Society, and a blood cancer survivor who has battled not one, not two, but three types of blood cancer.
Heart Disease in Lymphoma Survivors
Matthew Matasar is a hematology and oncology specialist at Memorial Sloan-Kettering Cancer Center in New York City. He has a Translational Research Program grant through The Leukemia & Lymphoma Society and is investigating which Hodgkin lymphoma survivors are at greater risk for developing heart disease after receiving radiation therapy to the chest and what diagnostic tests are best.
Sargramostim
Sargramostim is FDA approved
Tisagenlecleucel
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of